News - Momenta Pharmaceuticals


Current filters:

Momenta Pharmaceuticals

Popular Filters

US Appeals Court overturns Copaxone patent decision


Israel-based generics giant Teva Pharmaceutical Industries ((NYSE: TEVA) said on Friday (July 26) that…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Court ruling favors Mylan in Copaxone patent dispute


A US court has dismissed claims that US generic drugmaker Mylan (Nasdaq: MYL) infringed four patents…

CopaxoneGenericsMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsSandozTeva Pharmaceutical Industries

Future for biosimilars hugely promising, Momenta CEO tells GPhA meeting


Craig Wheeler, chief executive of Momenta Pharmaceuticals (Nasdaq: MNTA) discussed the promise and prospects…

BiotechnologyGenericsMarkets & MarketingMomenta PharmaceuticalsResearch

Watson settles over Exalgo; gets favorable news on enoxaparin


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) says that its subsidiary, Watson Laboratories,…

Cardio-vascularEnoxaparin Sodium InjectionExalgoGenericsLegalLovenoxMallinckrodtMomenta PharmaceuticalsNeurologicalNorth AmericaSanofiWatson Pharmaceuticals

Baxter taps Momenta expertise on biosimilars


In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster…

Baxter InternationalBiotechnologyGenericsLicensingMomenta PharmaceuticalsResearch

Teva prevails in Copaxone law suit with Mylan/Natco and Sandoz/Momenta


Israel-headquartered Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the US District Court for…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Back to top